A combination of nontoxic dietary and hyperbaric oxygen therapies effectively increased survival time in a mouse model of aggressive metastatic cancer, a research team from the Hyperbaric Biomedical Research Laboratory at the University of South Florida has found.
The study, “The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer,” was published online in PLOS ONE.
Led by Dominic D’Agostino, PhD, principal investigator in the Department of Molecular Pharmacology and Physiology at the USF Health Morsani College of Medicine, the research shows the effects of combining two nontoxic adjuvant cancer therapies, the ketogenic diet and hyperbaric oxygen therapy, in a mouse model of late-stage, metastatic cancer.
“Our study demonstrates the potential of these cost-effective, nontoxic therapies to contribute to current cancer treatment regimens and significantly improve the outcome of patients with advanced metastatic cancer,” D’Agostino said.
Metastasis, the spreading of cancer from the primary tumor to distant spots, is responsible for over 90 percent of cancer-related deaths in humans. A lack of available therapies effective against metastatic disease remains the largest obstacle in finding a cure for cancer.
In the study, mice with advanced metastatic cancer were fed either a standard highcarbohydrate diet or carbohydrate-restricted ketogenic diet. Mice on both diets also received hyperbaric oxygen therapy, which uses a special chamber to increase the amount of oxygen in the tissues.